Osiris Therapeutics (OTCMKTS:OSIR) is a biotechnology company specializing in regenerative medicine and bioactive tissue products. The company focuses on harnessing the properties of human placental membranes and mesenchymal stem cells to support healing in a variety of clinical settings. Through its BioSurgery business unit, Osiris develops, manufactures and markets advanced wound care and surgical products designed to address unmet medical needs in wound management, orthopedic repair and soft tissue reconstruction.
Central to Osiris’s product portfolio is the Grafix® family of placental membrane products, which are cleared by the U.S. Food and Drug Administration for use in chronic, acute and surgical wounds. These products leverage naturally occurring growth factors, cytokines and extracellular matrix components to support the body’s own regenerative processes. In addition, the company’s Stravix™ and Bio4™ offerings provide bioactive tissue solutions for obstetric, orthopedic and soft tissue applications, enabling physicians to enhance healing outcomes and reduce the risk of complications.
Founded in 1992 by researchers at the University of Minnesota, Osiris Therapeutics has been at the forefront of mesenchymal stem cell research and development. The company was among the first to isolate and characterize adult stem cells capable of modulating inflammation and promoting tissue regeneration. Over the years, Osiris has forged strategic collaborations and licensing agreements with leading medical device and pharmaceutical companies, including Smith & Nephew and Stryker, to extend the reach of its proprietary technologies to global markets.
Headquartered in Columbia, Maryland, Osiris operates a state-of-the-art manufacturing facility compliant with Good Tissue Practices and ISO standards. The company’s products are distributed in the United States, Europe, Canada, Australia and select emerging markets. Under the leadership of CEO Peter Friedli, Osiris continues to expand its BioSurgery business while exploring new regenerative medicine applications through research partnerships and clinical studies.
AI Generated. May Contain Errors.
Free OSIR Stock Alerts